Award Number: W81XWH-06-1-0788

TITLE: Recombinant Peptides as Biomarkers for Metastatic Breast Cancer Response

PRINCIPAL INVESTIGATOR: Roberto Diaz, M.D., Ph.D.

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center
Nashville, TN 37203

REPORT DATE: October 2007

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
1. REPORT DATE (DD-MM-YYYY) 2. REPORT TYPE Annual Summary 3. DATES COVERED (From - To) 25 Sep 2006 - 24 Sep 2007

4. TITLE AND SUBTITLE
Recombinant Peptides as Biomarkers for Metastatic Breast Cancer Response

5a. CONTRACT NUMBER
5b. GRANT NUMBER W81XWH-06-1-0788
5c. PROGRAM ELEMENT NUMBER
5d. PROJECT NUMBER
5e. TASK NUMBER
5f. WORK UNIT NUMBER

6. AUTHOR(S)
Roberto Diaz, M.D., Ph.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
Vanderbilt University Medical Center
Nashville, TN 37203

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
The overall objective of this Proposal is to rapidly and non-invasively assess metastatic breast cancer susceptibility to tyrosine kinase inhibitors (TKIs) by use of recombinant peptides that bind within tumors. We will then identify the receptor to which the recombinant peptide binds. We propose that this receptor protein becomes unveiled following therapy. These recombinant peptides in turn can be labeled with internal emitters to provide a means of non-invasive monitoring of tumor responsiveness to therapy. We propose that the peptide will bind to receptors within the tumor microvasculature that are specifically induced in response to therapy and are not present in untreated endothelium. These aims will test the central hypothesis that non-invasive assessment of breast tumor susceptibility to therapy can be achieved by use of recombinant peptides selected from phage-displayed libraries.

15. SUBJECT TERMS
Breast cancer, phage display, molecular imaging, personalized medicine

16. SECURITY CLASSIFICATION OF:
a. REPORT U
b. ABSTRACT U
c. THIS PAGE U

17. LIMITATION OF ABSTRACT
UU

18. NUMBER OF PAGES 11

19a. NAME OF RESPONSIBLE PERSON USAMRMC
19b. TELEPHONE NUMBER (include area code)
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>10</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>10</td>
</tr>
<tr>
<td>Conclusion</td>
<td>10</td>
</tr>
<tr>
<td>References</td>
<td>11</td>
</tr>
<tr>
<td>Appendices</td>
<td>11</td>
</tr>
</tbody>
</table>
1. INTRODUCTION

Presently, metastatic breast cancer response is measured by assessment of tumor volumes or by repeated biopsy to analyze pharmacodynamics. These methods of monitoring breast cancer response are inefficient because volume changes typically occur after patients are on therapy for prolonged time intervals. For that reason, we have developed the hypotheses that recombinant peptides from phage-displayed peptide libraries can be selected that bind to receptors activated in response to therapy. These peptides in turn can be labeled with internal emitters to provide a means to non-invasive monitoring of responsiveness to therapy. The physiologic response to therapy is seen within 24 hours of therapy, which provides a rapid assessment using non-invasive means. The overall objective of this Proposal is to rapidly and non-invasively assess metastatic breast cancer susceptibility to tyrosine kinase inhibitors (TKIs) by use of recombinant peptides that bind within tumors. We will then identify the receptor to which the recombinant peptide binds. We propose that this receptor protein becomes unveiled following therapy. These recombinant peptides in turn can be labeled with internal emitters to provide a means of non-invasive monitoring of tumor responsiveness to therapy. We propose that the peptide will bind to receptors within the tumor microvasculature that are specifically induced in response to therapy and are not present in untreated endothelium. These aims will test the central hypothesis that non-invasive assessment of breast tumor susceptibility to therapy can be achieved by use of recombinant peptides selected from phage-displayed libraries.

2. BODY

Statement of Work (SOW) Task 1. Noninvasive assessment of metastatic breast cancer vascular response to tyrosine kinase inhibitors by use of recombinant peptides from phage-displayed libraries:

Screening of phage displayed peptide libraries have been established to discover peptide ligands that bind to tumor vasculature, cancer cells, or specific molecular targets. Phage display technology allows for the insertion of random DNA sequences into the bacteriophage genome that in turn encode the capsid proteins, thereby providing peptides expressed on the phage surface that bind to cell surface molecules. In our laboratory, we have isolated the HVGGSSV peptide via in vivo biopanning of Lewis lung carcinoma (LLC) and glioma (GL261) after treatment with radiation alone using this technology. In a manuscript submitted for publication, our laboratory has shown that this peptide can detect susceptibility to treatment with tyrosine kinase inhibitors + radiation in various tumor models, including lung, brain, colon, and prostate. This peptide also recognizes breast cancer cells treated with TKI alone, and this data is presented under the SOW Task 2 heading.

We have previously reported that when compared to treatment with radiation or sunitinib alone, the combination of sunitinib and radiation resulted with more cell apoptosis, improved tumor growth control and reduced tumor angiogenesis. Therefore, we conducted in vivo biopanning to screen peptide candidates recovered from heterotopic and orthotopic gliomas (GL261) treated with sunitibib (40mg/kg) and radiation (3Gy). Sequence analysis of phage recovered from in vivo biopanning showed the following distribution: 1) GIRLRG–43.75%, 2) AARLY–37.5%, and 3) HMWRDSQ–18.75%. Since the GIRLRG phage is the one with the highest percent distribution in our studies, we proceeded to test whether the GIRLRG phage and peptide are able to detect treatment response in breast cancer tumor models.

Results from our laboratory have shown that peptides conjugated to near infrared imaging agents (NIR) are viable tools for rapid non-invasive imaging detection. Therefore, we have used this technique to replace our original plan to conjugate peptide to DOTA.

Sunitinib treatment elicits growth delay in mice implanted with MDA-MB-231 breast tumors.

First of all, we tested if continuous treatment of MDA-MB-231 cells with the tyrosine kinase inhibitor (TKI) sunitinib elicits tumor growth delay (Figure 1). We found that Sunitinib treatment is able to elicit growth delay in nude mice implanted with MDA-MB-231 tumors, and this difference is statistically significant (Figure 1B, P=0.001).
GIRLRG phage binds to Sunitinib-treated but not to untreated MDA-MB-231 breast tumors

In order to test the hypothesis that the GIRLRG phage could detect response to treatment of MDA tumor cells after they have been treated continuously with Sunitinib (Figure 1), MDA-MB-231 tumor cells were injected into the hind limb of nude mice. After the tumor was successfully implanted, the mice were treated with Sunitinib daily for 6 consecutive days x 2 cycles. The Alexa-Fluor labeled GIRLRG phage was then added and we found that the GIRLRG phage binds preferentially to the treated breast tumors (Figure 2).

GIRLRG phage binds to untreated and Sunitinib-treated MCF-7 breast tumors

We also conducted a preliminary study to test whether the GIRLRG phage is able to recognize treated MCF-7 breast cancer cells (Figure 3). To that effect, MCF-7 cells were implanted in the hind limbs of nude mice. Mice were treated systemically with either vehicle control or Sunitinib. The tumor in the right hind limb was irradiated with 3 Gy. Four hours after treatment, Alexa-Fluor labeled GIRLRG phage was added into the circulation and the mice were imaged with near infrared imaging at various time points. GIRLRG phage binding within treated tumors was detected within 24 hours and persisted beyond 96 hours. These preliminary studies showed strong binding in the Sunitinib-treated tumor, but also some binding in the control (untreated) tumor. Interestingly, binding was not detected in the combination of Sutent + XRT group.

Figure 1. Nude mice were implanted with MDA-MB231 breast cancer cells. When the tumor volume reached 0.3 cm³, all mice were treated with either Sutent (40 mg/kg) or vehicle control daily. In panel (A), 3 control and 3 treatment mice were treated daily for 5 days and then monitored. In panel (B), 7 control and 9 treated mice were treated daily for 6 days, rest one day, and then repeated for 2 weeks. For both panels, the arrow indicates end of therapy.

Figure 2. Alexa Fluor-labeled GIRLRG phage binding in treated heterotopic MDA-MB231 breast tumors. MDA tumors were implanted in the hind limb of nude mice. Where indicated, mice were treated with Sunitinib (40 mg/kg) or vehicle control daily for 6 consecutive days x 3 cycles. Biodistribution of the Alexa Fluor labeled phage in tumor-bearing mice was studied with near infrared imaging at 24 hours after the addition of the first treatment with Sunitinib during the third cycle. The GIRLRG phage binds preferentially to Sunitinib-treated breast tumors that are responding to treatment compared to the untreated control.

Figure 3. GIRLRG phage binds to untreated and Sunitinib-treated MCF-7 breast tumors We also conducted a preliminary study to test whether the GIRLRG phage is able to recognize treated MCF-7 breast cancer cells (Figure 3). To that effect, MCF-7 cells were implanted in the hind limbs of nude mice. Mice were treated systemically with either vehicle control or Sunitinib. The tumor in the right hind limb was irradiated with 3 Gy. Four hours after treatment, Alexa-Fluor labeled GIRLRG phage was added into the circulation and the mice were imaged with near infrared imaging at various time points. GIRLRG phage binding within treated tumors was detected within 24 hours and persisted beyond 96 hours. These preliminary studies showed strong binding in the Sunitinib-treated tumor, but also some binding in the control (untreated) tumor. Interestingly, binding was not detected in the combination of Sutent + XRT group.
GIRLRG phage binds to treated tumor blood vessels

The phage binding within tumors was confirmed with immunohistochemical staining. Anti-phage antibody stained the GIRLRG phage within treated tumor endothelium (Figure 4B), but not within untreated tumors (Figure 4A).

Selection of phage-displayed peptides that bind to the microvasculature of Sunitinib-treated breast tumors

We encountered a significant delay in the approval of our Animal Care protocol, so the in vivo biopanning using the phage display technology to isolated peptides that could be specific to breast cancer tumor models has just been concluded. In vivo biopanning was conducted with a T7 phage-based random peptide library. Four rounds of consecutive selections were performed. The results of the peptides isolated from MCF-7 and MDA-MB-231 tumors are shown below:

<table>
<thead>
<tr>
<th>Peptide Screening Results for MDA breast cancer tumors</th>
<th>Peptide Screening Results for MCF-7 breast cancer tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peptides Identified by Sequencing Analysis</td>
<td>Percent Distribution</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>----------------------</td>
</tr>
<tr>
<td>EGEVGLG</td>
<td>58%</td>
</tr>
<tr>
<td>MRRSVGS</td>
<td>14%</td>
</tr>
<tr>
<td>SSAVL</td>
<td>8%</td>
</tr>
<tr>
<td>VLI</td>
<td>8%</td>
</tr>
<tr>
<td>SAGSVAL</td>
<td>6%</td>
</tr>
<tr>
<td>FGVR</td>
<td>3%</td>
</tr>
<tr>
<td>GFWEGL</td>
<td>3%</td>
</tr>
</tbody>
</table>

Interestingly, all four peptides isolated from the MCF-7 selection are present in the MDA selection. There are three peptides that appear to be unique to the MDA selection. We will test and prioritize these peptides during the second year of this work to determine if they can detect the susceptibility of metastatic breast cancer cells responding to treatment.
**SOW Task 2. To determine whether peptide binding to treated metastatic breast cancers correlate with biological response.**

Most of the studies for this proposal this year were conducted with the GIRLRG phage and peptide. This sequence was originally isolated in our laboratory from a selection of glioma tumors, but based on our previous experience, we tested whether this sequence could also be detected in breast cancer tumor models.

**The GIRLRG peptide binds to both control and Sunitinib +/- XRT treated tumors in MDA xenografts**

In order to determine if the GIRLRG peptide is the functional motif during binding to treated tumors, the GIRLRG peptide (NH2-KKGGGGIRLRG-COOH) was synthesized and labeled with Alexa-Fluor and Biotin in each of the lysines in the N-terminal group. The three glycine residues were placed at the N-terminus to separate the GIRLRG peptide from the Alexa-Fluor. Near infrared imaging was used to monitor the biodistribution of the peptide in tumor-bearing mice treated with varying doses of Sunitinib +/- radiation. We found that the GIRLRG peptide binds to both control and treated MDA tumors (Figure 5).

---

**Figure 5.** GIRLRG peptide binds to both control and Sunitinib +/- XRT treated tumors in MDA xenografts. Biotinilated GIRLRG peptide + Streptavidin-Alexa Fluor conjugated peptide was injected 4 hours after the first dose of treatment. Near infrared images were taken at 24h, 48h, and 72h. Radiance measurements are shown on the right.
HVGGSSV peptide can detect susceptibility of treatment response in MDA tumors

To determine whether the HVGGSSV peptide can be used to distinguish treatment response within breast cancer tumors, we studied heterotopic tumors of MDA breast cells (Figure 6). The HVGGSSV peptide (NH2-GGGNHVGGSSV-COOH) was synthesized and labeled with Cy7 at the N-terminal amine group. Three glycine residues were placed at the N-terminus to separate the HVGGSSV petide from Cy7. NIR imaging was used to monitor the biodistribution of the peptide in tumor-bearing mice treated with varying doses of Sunitinib +/- irradiation. Nude mice bearing MDA-MB-231 tumors were treated with 3 Gy irradiation following injection of Sunitinib (Figure 6A). HVGGSSV peptide binding was not detected in untreated tumors (data not shown), whereas tumors treated with sunitinib and radiation showed near infrared imaging of peptide binding within 24 hours of injection. The treated cells showed significant increase in radianse compared to untreated controls (p<0.05, n=3). To determine whether radiance from peptide binding in tumors correlated with tumor response, we studied the dose-dependent response to sunitinib in MDA-MB-231 breast cancer cells (Figure 6B). MDA-MB-231 breast cancer cells were implanted into the hind limb of mice that were then treated for five consecutive days. The combination of Sunitinib with X-ray irradiation resulted in the most efficient tumor growth control, and tumors responded to high dose treatment (40 mg/kg of Sunitinib), but not 4 mg/kg, when the Sunitinib was used alone (Figure 6B). After the first treatment, Cy7-labeled peptide was injected into tail vein of the tumor-bearing mice, NIR images were captured, and the radiance in tumors was measured. We found a linear correlation for peptide binding (relative radianse) and tumor response (fold change in tumor volume) to treatment that is statistically significant.

Figure 6. HVGGSSV peptide binding detects response to therapy in a breast cancer tumor model. (A) MDA-MB-231 breast cancer cells were injected subcutaneously into the hind limb of nude mice. The tumor bearing mice were treated with sunitinib for one hour prior to irradiation. Cy7-labeled HVGGSSV peptide was injected intravenously 4 hours after treatment. Shown are NIR images obtained 48 hours after peptide injection. Irradiated tumors are indicated by arrows. (B) Shown is the linear correlation of peptide binding (relative radianse) to tumor response (tumor volume fold change) in human breast cancer MDA-MB-231 murine hind limb tumors (n=5 for each group). Radiance of peptide binding within tumors correlated with tumor growth attenuation (R²=0.868; p<0.01).
**SOW Task 3. Identification and characterization of radiation-induced antigenic targets in metastatic breast tumor vessels.**

**Homology of GIRLRG peptide**

BLAST search was performed for each peptide. BLAST search for the GIRLRG peptide shows that the “IRLRG” sequence is also present in the transforming growth factor alpha, which is a ligand for EGFR; the “GIRLR” sequence is also present in the fibroblast growth factor receptor 4 (FGFR4) and in thyroglobulin. For FGFR4, it has been shown that a truncated form results in pituitary tumors; it interacts with N-cadherin and can cause impaired cell-matrix adhesiveness; is associated with bladder cancer prognosis; correlates with survival in head and neck squamous cell carcinoma; and is associated with resistance to adjuvant therapy in primary breast cancer.

**Homology of GIRLRG Peptide**

- Endothelial cell growth factor 1 (platelet-derived)
- transforming growth factor, alpha, isoform CRA_e
- fibroblast growth factor receptor 4, isoform CRA_a
- Thyroglobulin
- Rho guanine nucleotide exchange factor (GEF) 11
- Monooxygenase, DBH-like 1
- protein-coupled receptor 124, isoform CRA_a
- Beta-1,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (N-glycosyl-oligosaccharide-glycoprotein N-acetylglucosaminyltransferase III) (N-acetylglucosaminyltransferase III) (Gnt-III) (GlcNAc-T III)
- craniofacial development protein 1, isoform CRA_a
- serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 13

**Levels of expression of various putative receptor candidates for GIRLRG**

We subsequently conducted co-culture experiments utilizing MCF-7 grown together with HUVEC cells. We then treated the cells with Sunitinib +/- radiation, harvested them 4 hours after treatment, and then performed Western blot analyses to determine the level of expression of various of the putative candidates for receptor for GIRLRG.

**Figure 7. (A) Co-culture experiments to determine expression of FGFR-4 with Sunitinib +/- XRT.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Western Blot</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Huvec+MCF-7 Control</td>
<td></td>
</tr>
<tr>
<td>2. Huvec+MCF-7 Sutent (5uM)</td>
<td></td>
</tr>
<tr>
<td>3. Huvec+MCF-7 XRT (3Gy)</td>
<td></td>
</tr>
<tr>
<td>4. Huvec+MCF-7 Sutent+XRT</td>
<td></td>
</tr>
</tbody>
</table>

Results: In co-culture system with MCF-7 cells FGFR4 appears to increase with Treatment groups compared to control

**Figure 7. (B) Co-culture experiments to determine expression of PD-ECGF with Sunitinib +/- XRT.**

<table>
<thead>
<tr>
<th>Group</th>
<th>Western Blot</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Huvec+MCF-7 Control</td>
<td></td>
</tr>
<tr>
<td>2. Huvec+MCF-7 Sutent (5uM)</td>
<td></td>
</tr>
<tr>
<td>3. Huvec+MCF-7 XRT (3Gy)</td>
<td></td>
</tr>
<tr>
<td>4. Huvec+MCF-7 Sutent+XRT</td>
<td></td>
</tr>
</tbody>
</table>

Results: In co-culture system with MCF-7 cells PD-ECGF appears to increase with Treatment groups.

Additional efforts to continue to identify potential targets and to isolate the receptor have been initiated. Thus, affinity purification using HUVEC co-cultures with breast cancer cells are being investigated.
3. KEY RESEARCH ACCOMPLISHMENTS

- HVGGSSV peptide can detect susceptibility of treatment response in MDA tumors.
- GIRLRG phage binds preferentially to MDA tumors treated continuously with Sunitinib compared to untreated control.
- GIRLRG peptide binds to both untreated and single dose Sunitinib-treated breast cancer tumors.
- We have identified four peptide sequences (EGEVGLG, SSAVL, MRRSVGS, and FGVR) that have potential to elicit binding to Sunitinib-treated breast tumors.

4. REPORTABLE OUTCOMES


5. CONCLUSION

We have identified peptides, like HVGGSSV, that bind to breast tumors treated with Sunitinib, and that the level of binding correlates with tumor susceptibility to therapy. Additionally, the GIRLRG phage elicits differential binding to MDA and MCF-7 cells and therefore warrants further investigation as to what is the putative receptor that is present even in untreated MCF-7 cells. This could open the possibility of utilizing this peptide for potential targeted drug delivery systems.

Furthermore, the identification of novel peptides (EGEVGLG, SSAVL, MRRSVGS, and FGVR) isolated specifically from both breast cancer tumor cells (MCF-7 and MDA) treated with Sunitinib shows potential for further investigation and validation of these peptides/phage with additional response to other receptor tyrosine kinase inhibitors. In addition, we would also like to prioritize these peptides based on their ability to discern treatment response within metastatic breast tumors.
Therefore, phage display technology promises to aid the discovery of useful imaging peptides that facilitate molecular imaging of breast cancer pharmacodynamic response to therapy with tyrosine kinase inhibitors. We have shown that this technology can be used to select phage displayed peptides that distinguish treated from untreated breast tumors. These peptides can serve as “molecular beacons” that bind to susceptible cancers, allowing for a more rapid assessment of cancer responsiveness to therapy. Thus, rapid noninvasive assessment of pharmacodynamic response of breast cancer promises to minimize the duration of ineffective treatment regimens in cancer patients and speed drug development.

6. REFERENCES

7. APPENDICES
None included.